fulltext.study @t Gmail

EGRF conjugated PEGylated nanographene oxide for targeted chemotherapy and photothermal therapy

Paper ID Volume ID Publish Year Pages File Format Full-Text
6342 484 2013 11 PDF Available
Title
EGRF conjugated PEGylated nanographene oxide for targeted chemotherapy and photothermal therapy
Abstract

Low accumulation of chemotherapeutic agent in tumor tissue and multidrug resistance (MDR) present a major obstacle to curing cancer treatment. Therefore, how to combine several therapeutics in one system is a key issue to overcome the problem. Here, we demonstrate epidermal growth factor receptor (EGFR) antibody-conjugated PEGylated nanographene oxide (PEG-NGO) to carry epirubicin (EPI) for tumor targeting and triple-therapeutics (growth signal blocking, chemotherapy, photothermal therapy) in tumor treatment. This synergistic targeted treatment simultaneously enhances the local drug concentration (6.3-fold) and performs the ultra-efficient tumor suppression to significantly prolong the mice survival (over the course of 50 days).

Keywords
Nanographene oxide; Tumor targeting; Chemotherapy; Photothermal therapy; Growth signal blocking; EGFR
First Page Preview
EGRF conjugated PEGylated nanographene oxide for targeted chemotherapy and photothermal therapy
Get Full-Text Now
Don't Miss Today's Special Offer
Price was $35.95
You save - $31
Price after discount Only $4.95
100% Money Back Guarantee
Full-text PDF Download
Online Support
Any Questions? feel free to contact us
Publisher
Database: Elsevier - ScienceDirect
Journal: Biomaterials - Volume 34, Issue 29, September 2013, Pages 7204–7214
Authors
, , , , , , , , , , , , , ,
Subjects
Physical Sciences and Engineering Chemical Engineering Bioengineering
Get Full-Text Now
Don't Miss Today's Special Offer
Price was $35.95
You save - $31
Price after discount Only $4.95
100% Money Back Guarantee
Full-text PDF Download
Online Support
Any Questions? feel free to contact us